查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552555

焦慮症和憂鬱症治療市場規模、佔有率、趨勢分析報告：按藥物、適應症、分銷管道、地區和細分市場預測，2024-2030年

Anxiety Disorders And Depression Treatment Market Size, Share & Trends Analysis Report By Drug (Antidepressants, Anxiolytics, Anticonvulsants, & Others), By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

焦慮症和憂鬱症治療市場的成長和趨勢

預計到2030年，全球焦慮憂鬱症治療市場規模將達到158.8億美元。

2024年至2030年的複合年成長率預計為3.6%。全球憂鬱症盛行率上升預計將推動未來幾年的市場成長。近年來，由於設備和心理治療的採用增加，抗憂鬱症的需求有所下降。

容易患憂鬱症的老年人口不斷增加，恐懼症和整體焦慮症等焦慮症的迅速增加，將進一步推動預測期內治療精神疾病的抗憂鬱症的需求不斷成長。此外，採用先進技術的治療方法，例如用於大腦刺激的醫療植入和使用基於智慧型手機的應用程式的虛擬實境暴露療法，為患者提供了創新的治療選擇。

焦慮症和憂鬱症治療市場報告亮點

  • 目前，抗憂鬱症領域佔據了最大的收益佔有率。然而，由於與這些治療相關的不利事件發生率不斷增加，預計該領域的成長將會下降。
  • 抗憂鬱症市場的下滑是由於品牌藥專利到期以及採用具有成本效益的生物學名藥所致。
  • 同時，Duloxetine、Fezzima 和 Brintellix 等新藥的採用預計將在未來幾年推動治療需求。
  • 此外，由於與藥品相比副作用較少，醫療保健專業人員擴大採用個人化治療和設備，因此預計個人化治療和設備領域將實現最快的成長。
  • 由於多種藥物的可用性以及該地區憂鬱症的高盛行率，北美地區的焦慮和憂鬱症治療已達到飽和水平。
  • 由於學名藥在市場上佔據主導地位，抗憂鬱症的收益預計在預測期內將下降。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章：焦慮症和憂鬱症治療市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 焦慮症和憂鬱症治療市場的變數市場分析工具
    • 波特的分析
    • PESTEL分析

第4章焦慮症和憂鬱症治療市場的變數：藥物、估計和趨勢分析

  • 細分儀表板
  • 焦慮症與憂鬱症治療市場變數市場：藥品波動分析，百萬美元，2023 年和 2030 年
  • 抗憂鬱症
    • 2018-2030年抗憂鬱症市場收益估計與預測
  • 抗焦慮藥
    • 2018-2030年抗焦慮藥物市場收益估計與預測
  • 抗驚厥藥
    • 2018-2030年抗癲癇藥物市場收益估計與預測
  • 去甲腎上腺素促效劑
    • 去甲腎上腺素能促效劑市場收益估計與預測，2018-2030
  • 非典型抗精神病藥
    • 2018-2030年非典型抗精神病藥物市場收益估計與預測

第5章焦慮症與憂鬱症治療市場：適應症、估計與趨勢分析

  • 細分儀表板
  • 焦慮症與憂鬱症治療市場：適應症變異分析，百萬美元，2023 年和 2030 年
  • 憂鬱症
  • 焦慮症

第6章焦慮症與憂鬱症治療市場：通路、估計與趨勢分析

  • 細分儀表板
  • 焦慮症和憂鬱症治療市場：分銷管道變化分析，百萬美元，2023 年和 2030 年
  • 醫院
  • 零售藥房
  • 網路藥房

第7章焦慮症與憂鬱症治療市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區分類的焦慮症和憂鬱症治療市場佔有率，百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Pfizers Inc.
    • H. Lundbeck A/S
    • Glaxo SmithKline Pharmaceuticals Ltd.
    • Merck &Co., Inc.
    • Eli Lilly &Company
    • AstraZeneca
    • Bristol-Myers Squibb
    • Johnson &Johnson
    • AbbVie Inc.
    • Sanofi
簡介目錄
Product Code: GVR-1-68038-731-5

Anxiety Disorders And Depression Treatment Market Growth & Trends:

The global anxiety disorders and depression treatment market is expected to reach a value of USD 15.88 billion by 2030. The market is projected to grow at a CAGR of 3.6% from 2024 to 2030. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Anxiety Disorders And Depression Treatment Market Report Highlights:

  • Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment's growth is expected to wane
  • Patent expiration of branded medicines and the introduction of generic biosimilars, which are cost-effective, are responsible for the shrinking market of antidepressants
  • On the other hand, the introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, is predicted to fuel the demand for therapeutics in the coming years
  • Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
  • North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
  • The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Anxiety Disorders and Depression Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Anxiety Disorders and Depression Treatment Market Variables Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Anxiety Disorders and Depression Treatment Market Variables : Drugs Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Anxiety Disorders and Depression Treatment Market Variables Market: Solution Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Antidepressants
    • 4.3.1. Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Anxiolytics
    • 4.4.1. Anxiolytics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Anticonvulsants
    • 4.5.1. Anticonvulsants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Noradrenergic Agents
    • 4.6.1. Noradrenergic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Atypical Antipsychotics
    • 4.7.1. Atypical Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Anxiety Disorders and Depression Treatment Market : Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Anxiety Disorders and Depression Treatment Market: Technology Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Depression
    • 5.3.1. Depression Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Anxiety
    • 5.4.1. Anxiety Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Anxiety Disorders and Depression Treatment Market : Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Anxiety Disorders and Depression Treatment Market: End-user Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Anxiety Disorders and Depression Treatment Market : Regional Estimates & Trend Analysis

  • 7.1. Anxiety Disorders and Depression Treatment Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizers Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. H. Lundbeck A/S
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Glaxo SmithKline Pharmaceuticals Ltd.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Merck & Co., Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Eli Lilly & Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. AstraZeneca
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bristol-Myers Squibb
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Johnson & Johnson
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. AbbVie Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Sanofi
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives